Bipolar Research Today is a free monthly online journal that collates and summarizes the latest research about Bipolar, including details on bipolar disorder, symptoms, treatment, depression, medication.

Volume 7 (2010), Issue 9 (September)

1. Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients.
   Psychiatr Serv, 61(9): 892-8. [Abstract] [Full-text]
2. Best practices: disseminating best practices for bipolar disorder treatment in a correctional population.
   Psychiatr Serv, 61(9): 865-7. [Abstract] [Full-text]
3. Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder.
   Psychol Med. [Abstract] [Full-text]
4. Novel association strategy with copy number variation for identifying new risk Loci of human diseases.
   PLoS One, 5(8). [Abstract] [Full-text]
5. History of suffocation, state-trait anxiety, and anxiety sensitivity in predicting 35% carbon dioxide-induced panic.
   Psychiatry Res, 179(2): 194-7. [Abstract] [Full-text]
6. Frontonasal dysmorphology in bipolar disorder by 3D laser surface imaging and geometric morphometrics: comparisons with schizophrenia.
   Schizophr Res, 122(1): 63-71. [Abstract] [Full-text]
7. Characteristics and Clinical Changes during Hospitalization in Bipolar and Psychotic Disorder Patients with versus without Substance-Use Disorders.
   Pharmacopsychiatry, 43(6): 225-32. [Abstract] [Full-text]
8. Catechol O-methyltransferase variants and cognitive performance in schizophrenia and bipolar disorder versus controls.
   Schizophr Res, 122(1): 31-7. [Abstract] [Full-text]
9. Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug.
   J Affect Disord. [Abstract] [Full-text]
10. Pharmacotherapy for the treatment of acute bipolar ii depression: current evidence.
    J Clin Psychiatry. [Abstract] [Full-text]
11. Detection of subclinical depression in bipolar disorder: a cross-sectional, 4-month prospective follow-up study at community mental health services (SIN-DEPRES).
    J Clin Psychiatry. [Abstract] [Full-text]
12. Translational research in bipolar disorder: emerging insights from genetically based models.
    Mol Psychiatry, 15(9): 883-95. [Abstract] [Full-text]
13. Olfactory identification and preference in bipolar disorder and schizophrenia.
    Eur Arch Psychiatry Clin Neurosci. [Abstract] [Full-text]
14. Genetic variation in CACNA1C affects brain circuitries related to mental illness.
    Arch Gen Psychiatry, 67(9): 939-45. [Abstract] [Full-text]
15. Bipolar disorder and violent crime: new evidence from population-based longitudinal studies and systematic review.
    Arch Gen Psychiatry, 67(9): 931-8. [Abstract] [Full-text]
16. Lifetime prevalence and correlates of suicidal ideation, plan, and single and multiple attempts in a Korean nationwide study.
    J Nerv Ment Dis, 198(9): 643-6. [Abstract] [Full-text]
17. Treatment delay and excessive substance use in bipolar disorder.
    J Nerv Ment Dis, 198(9): 628-33. [Abstract] [Full-text]
18. Lamotrigine: when and where does it act in affective disorders? A systematic review.
    J Psychopharmacol. [Abstract] [Full-text]
19. Clinical predictors associated with duration of repetitive transcranial magnetic stimulation treatment for remission in bipolar depression: a naturalistic study.
    J Nerv Ment Dis, 198(9): 679-81. [Abstract] [Full-text]
20. Perceptions of illness in self and in others among patients with bipolar disorder.
    Int J Soc Psychiatry, 56(5): 462-70. [Abstract] [Full-text]
21. An investigation into the experience of self-conscious emotions in individuals with bipolar disorder, unipolar depression and non-psychiatric controls.
    Clin Psychol Psychother, 17(5): 395-405. [Abstract] [Full-text]
22. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder.
    Am J Psychiatry, 167(9): 1116-24. [Abstract] [Full-text]
23. Transition to Mania During Treatment of Bipolar Depression.
    Neuropsychopharmacology. [Abstract] [Full-text]
24. Depressive and manic symptoms are not opposite poles in bipolar disorder.
    Acta Psychiatr Scand. [Abstract] [Full-text]
25. Glutamatergic modulators: the future of treating mood disorders?
    Harv Rev Psychiatry, 18(5): 293-303. [Abstract] [Full-text]
26. The pharmacological treatment of bipolar disorder: the question of modern advances.
    Harv Rev Psychiatry, 18(5): 266-78. [Abstract] [Full-text]
27. Quetiapine XR: current status for the treatment of major depressive disorder.
    Prog Neuropsychopharmacol Biol Psychiatry, 34(7): 1165-73. [Abstract] [Full-text]
28. Association between CLOCK 3111T/C and preferred circadian phase in Korean patients with bipolar disorder.
    Prog Neuropsychopharmacol Biol Psychiatry, 34(7): 1196-201. [Abstract] [Full-text]
29. Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population.
    Prog Neuropsychopharmacol Biol Psychiatry, 34(7): 1243-9. [Abstract] [Full-text]
30. Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers.
    Prog Neuropsychopharmacol Biol Psychiatry, 34(7): 1322-6. [Abstract] [Full-text]
31. Neuropsychological functioning in adult bipolar disorder and ADHD patients: A comparative study.
    Psychiatry Res. [Abstract] [Full-text]
32. Bipolar disorder patients have similar levels of education but lower socio-economic status than the general population.
    J Affect Disord. [Abstract] [Full-text]
33. Therapeutic potential of interleukin-6 antagonism in bipolar disorder.
    Med Hypotheses. [Abstract] [Full-text]
34. Comparing clinical and neurocognitive features of the schizophrenia prodrome to the bipolar prodrome.
    Schizophr Res, 123(1): 59-63. [Abstract] [Full-text]
35. SRD5A2 is associated with increased cortisol metabolism in schizophrenia spectrum disorders.
    Prog Neuropsychopharmacol Biol Psychiatry. [Abstract] [Full-text]
36. Quetiapine: novel uses in the treatment of depressive and anxiety disorders.
    Expert Opin Investig Drugs, 19(10): 1187-204. [Abstract] [Full-text]
37. Neurocognitive and Neuroimaging Predictors of Clinical Outcome in Bipolar Disorder.
    Curr Psychiatry Rep. [Abstract] [Full-text]
38. Downregulation of the cAMP/PKA Pathway in PC12 Cells Overexpressing NCS-1.
    Cell Mol Neurobiol. [Abstract] [Full-text]
39. The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function.
    Mol Psychiatry. [Abstract] [Full-text]
40. Lithium Differentially Affects Clock Gene Expression in Serum-Shocked nih-3t3 Cells.
    J Psychopharmacol. [Abstract] [Full-text]
41. Long-term naturalistic follow-up of lithium augmentation: Relevance to bipolarity.
    J Affect Disord. [Abstract] [Full-text]
42. A comprehensive review and model of putative prodromal features of bipolar affective disorder.
    Psychol Med. [Abstract] [Full-text]
43. C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients.
    J Clin Psychopharmacol, 30(5): 512-7. [Abstract] [Full-text]
44. Is glycogen synthase kinase-3 a central modulator in mood regulation?
    Neuropsychopharmacology, 35(11): 2143-54. [Abstract] [Full-text]
45. Increased cortical expression of an RNA editing enzyme occurs in major depressive suicide victims.
    Neuroreport, 21(15): 993-7. [Abstract] [Full-text]
46. Clinical characteristics and resource utilization of patients with bipolar disorder who have frequent psychiatric interventions.
    J Med Econ, 13(3): 552-8. [Abstract] [Full-text]
47. Mental Health Service Use Before and After Diagnosis of Early-Onset Bipolar Disorder.
    J Behav Health Serv Res. [Abstract] [Full-text]
48. Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors.
    Synapse, 64(11): 870-4. [Abstract] [Full-text]
49. Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors.
    Synapse, 64(11): 870-4. [Abstract] [Full-text]
50. Increased cortical expression of an RNA editing enzyme occurs in major depressive suicide victims.
    Neuroreport, 21(15): 993-7. [Abstract] [Full-text]
51. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania.
    J Affect Disord. [Abstract] [Full-text]
52. Genome-wide approaches to schizophrenia.
    Brain Res Bull, 83(3): 93-102. [Abstract] [Full-text]
53. Human behavioral informatics in genetic studies of neuropsychiatric disease: multivariate profile-based analysis.
    Brain Res Bull, 83(3): 177-88. [Abstract] [Full-text]
54. Mindfulness based cognitive therapy for psychiatric disorders: A systematic review and meta-analysis.
    Psychiatry Res. [Abstract] [Full-text]
55. Brain-derived neurotrophic factor signalling mediates antidepressant effects of lamotrigine.
    Int J Neuropsychopharmacol. [Abstract] [Full-text]
56. Psychometric properties of the Chinese version of the Bipolar Spectrum Diagnostic Scale.
    J Clin Nurs, 19(19): 2787-94. [Abstract] [Full-text]
57. Drug interaction between carbapenems and extended-release divalproex sodium in a patient with schizoaffective disorder.
    Gen Hosp Psychiatry, 32(5): 560.e1-3. [Abstract] [Full-text]
58. Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder.
    Gen Hosp Psychiatry, 32(5): 556-8. [Abstract] [Full-text]
59. Neurocognitive deficits and personality traits among euthymic patients with mood disorders in late life.
    J Neurol Sci. [Abstract] [Full-text]
60. Convergent integration of animal model and human studies of bipolar disorder (manic-depressive illness).
    Curr Opin Pharmacol, 10(5): 594-600. [Abstract] [Full-text]
61. Work impairment in bipolar disorder patients--results from a two-year observational study (EMBLEM).
    Eur Psychiatry, 25(6): 338-44. [Abstract] [Full-text]
62. Influence of the serotonin transporter gene polymorphism, cannabis and childhood sexual abuse on phenotype of bipolar disorder: a preliminary study.
    Eur Psychiatry, 25(6): 323-7. [Abstract] [Full-text]
63. Predicting the course and outcome of bipolar disorder: a review.
    Eur Psychiatry, 25(6): 328-33. [Abstract] [Full-text]
64. Mindfulness-based cognitive therapy for bipolar disorder: a feasibility trial.
    Eur Psychiatry, 25(6): 334-7. [Abstract] [Full-text]
65. The Bipolar Spectrum: Myth or Reality?
    Curr Psychiatry Rep. [Abstract] [Full-text]
66. CRY2 is associated with rapid cycling in bipolar disorder patients.
    PLoS One, 5(9): e12632. [Abstract] [Full-text]
67. Correlates of first-episode polarity in a French cohort of 1089 bipolar I disorder patients: Role of temperaments and triggering events.
    J Affect Disord. [Abstract] [Full-text]
68. Emotion processing influences working memory circuits in pediatric bipolar disorder and attention-deficit/hyperactivity disorder.
    J Am Acad Child Adolesc Psychiatry, 49(10): 1064-80. [Abstract] [Full-text]
69. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.
    Expert Opin Pharmacother, 11(15): 2557-67. [Abstract] [Full-text]
70. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines.
    J Psychiatr Pract, 16(5): 306-24. [Abstract] [Full-text]
71. Physical treatments for bipolar disorder: A review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques.
    J Affect Disord. [Abstract] [Full-text]
72. Child Mania Rating Scale-Parent Version: A valid measure of symptom change due to pharmacotherapy.
    J Affect Disord. [Abstract] [Full-text]
73. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia.
    Mol Psychiatry, 15(10): 1016-22. [Abstract] [Full-text]
74. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance.
    Int Clin Psychopharmacol. [Abstract] [Full-text]
75. Decision making in euthymic bipolar I and bipolar II disorders.
    Psychol Med. [Abstract] [Full-text]
76. The Child Behavior Checklist-Dysregulation Profile predicts substance use, suicidality, and functional impairment: a longitudinal analysis.
    J Child Psychol Psychiatry. [Abstract] [Full-text]
77. Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-β.
    Pharmacogenomics J, 10(5): 408-17. [Abstract] [Full-text]
78. Lateral ventricle differences between first-episode schizophrenia and first-episode psychotic bipolar disorder: A population-based morphometric MRI study.
    World J Biol Psychiatry, 11(7): 873-87. [Abstract] [Full-text]
79. Impact of executive function deficits in youth with bipolar I disorder: A controlled study.
    Psychiatry Res. [Abstract] [Full-text]
80. Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood.
    Am J Med Genet B Neuropsychiatr Genet, 153(7): 1336-41. [Abstract] [Full-text]
81. The Bipolar Association Case-Control Study (BACCS) and meta-analysis: No association with the 5,10-Methylenetetrahydrofolate reductase gene and bipolar disorder.
    Am J Med Genet B Neuropsychiatr Genet, 153(7): 1298-304. [Abstract] [Full-text]
82. Variation at the GABAA receptor gene, Rho 1 (GABRR1) associated with susceptibility to bipolar schizoaffective disorder.
    Am J Med Genet B Neuropsychiatr Genet, 153(7): 1347-9. [Abstract] [Full-text]
83. Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder.
    Am J Med Genet B Neuropsychiatr Genet, 153(7): 1318-28. [Abstract] [Full-text]
84. Psychiatric disorders in temporal lobe epilepsy: an overview from a tertiary service in Brazil.
    Seizure, 19(8): 479-84. [Abstract] [Full-text]
85. Association analysis between polymorphisms in the myo-inositol monophosphatase 2 (IMPA2) gene and bipolar disorder.
    Prog Neuropsychopharmacol Biol Psychiatry. [Abstract] [Full-text]
86. Autistic and psychiatric findings associated with the 3q29 microdeletion syndrome: case report and review.
    Am J Med Genet A, 152(10): 2459-67. [Abstract] [Full-text]
87. The role of Wnt signaling and its interaction with diverse mechanisms of cellular apoptosis in the pathophysiology of bipolar disorder.
    Prog Neuropsychopharmacol Biol Psychiatry. [Abstract] [Full-text]
88. Reduced right posterior hippocampal volume in women with recurrent familial pure depressive disorder.
    Psychiatry Res, 184(1): 23-8. [Abstract] [Full-text]
89. Psychodynamic-oriented psychological assessment predicts evolution to schizophrenia at 8-year follow-up in adolescents hospitalized for a manic/mixed episode: Interest of an overall subjective rating.
    J Physiol Paris. [Abstract] [Full-text]
90. An investigation of candidate regions for association with bipolar disorder.
    Am J Med Genet B Neuropsychiatr Genet, 153(7): 1292-7. [Abstract] [Full-text]
91. Association analysis of PALB2 and BRCA2 in bipolar disorder and schizophrenia in a scandinavian case-control sample.
    Am J Med Genet B Neuropsychiatr Genet, 153(7): 1276-82. [Abstract] [Full-text]
92. Binge eating disorder and menstrual cycle in unmedicated women with bipolar disorder.
    J Affect Disord. [Abstract] [Full-text]
93. Comorbid anxiety in children and adolescents with bipolar spectrum disorders: prevalence and clinical correlates.
    J Clin Psychiatry. [Abstract] [Full-text]
94. Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia.
    J Clin Psychiatry. [Abstract] [Full-text]
95. Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the vitoria prospective naturalistic study in Spain.
    J Clin Psychiatry. [Abstract] [Full-text]
96. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the systematic treatment enhancement program for bipolar disorder.
    J Clin Psychiatry. [Abstract] [Full-text]
97. Impairment of verbal learning and memory and executive function in unaffected siblings of probands with bipolar disorder.
    Bipolar Disord, 12(6): 647-56. [Abstract] [Full-text]
98. Autoimmune diseases, bipolar disorder, and non-affective psychosis.
    Bipolar Disord, 12(6): 638-46. [Abstract] [Full-text]
99. Family-focused treatment for caregivers of patients with bipolar disorder.
    Bipolar Disord, 12(6): 627-37. [Abstract] [Full-text]
100. The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
     Bipolar Disord, 12(6): 616-26. [Abstract] [Full-text]
101. The common adolescent bipolar phenotype shows positive biases in emotional processing.
     Bipolar Disord, 12(6): 606-15. [Abstract] [Full-text]
102. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder.
     Bipolar Disord, 12(6): 593-605. [Abstract] [Full-text]
103. Self-esteem in remitted bipolar disorder patients: a meta-analysis.
     Bipolar Disord, 12(6): 585-92. [Abstract] [Full-text]
104. Reduced right posterior hippocampal volume in women with recurrent familial pure depressive disorder.
     Psychiatry Res, 184(1): 23-8. [Abstract] [Full-text]
105. Demonstration of disturbed activity of the lateral amygdaloid nucleus projection neurons in depressed patients by the AgNOR staining method.
     J Affect Disord, 126(3): 402-10. [Abstract] [Full-text]
106. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study.
     J Affect Disord, 126(3): 453-7. [Abstract] [Full-text]
107. Bipolar disorder and metabolic syndrome: an international perspective.
     J Affect Disord, 126(3): 366-87. [Abstract] [Full-text]
108. Cytokine levels in euthymic bipolar patients.
     J Affect Disord, 126(3): 458-62. [Abstract] [Full-text]
109. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.
     J Affect Disord, 126(3): 358-65. [Abstract] [Full-text]
110. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.
     Pharmacol Ther, 128(2): 281-304. [Abstract] [Full-text]
111. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007).
     Eur Neuropsychopharmacol, 20(11): 776-83. [Abstract] [Full-text]
112. Switching to Hypomania and Mania: Differential Neurochemical, Neuropsychological, and Pharmacologic Triggers and Their Mechanisms.
     Curr Psychiatry Rep. [Abstract] [Full-text]
113. New Ways to Classify Bipolar Disorders: Going from Categorical Groups to Symptom Clusters or Dimensions.
     Curr Psychiatry Rep. [Abstract] [Full-text]
114. Animal models of neuropsychiatric disorders.
     Nat Neurosci, 13(10): 1161-9. [Abstract] [Full-text]
115. Automatic Bayesian classification of healthy controls, bipolar disorder and schizophrenia using intrinsic connectivity maps from fMRI data.
     IEEE Trans Biomed Eng. [Abstract] [Full-text]
116. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.
     Int J Neuropsychopharmacol. [Abstract] [Full-text]
117. Altered expression and coregulation of dopamine signalling genes in schizophrenia and bipolar disorder: (Altered expression of dopamine signalling genes. …).
     Neuropathol Appl Neurobiol. [Abstract] [Full-text]
118. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007).
     Eur Neuropsychopharmacol, 20(11): 776-83. [Abstract] [Full-text]
119. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.
     Pharmacol Ther, 128(2): 281-304. [Abstract] [Full-text]
120. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study.
     J Affect Disord, 126(3): 453-7. [Abstract] [Full-text]
121. Bipolar disorder and metabolic syndrome: an international perspective.
     J Affect Disord, 126(3): 366-87. [Abstract] [Full-text]
122. Cytokine levels in euthymic bipolar patients.
     J Affect Disord, 126(3): 458-62. [Abstract] [Full-text]
123. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.
     J Affect Disord, 126(3): 358-65. [Abstract] [Full-text]
124. Demonstration of disturbed activity of the lateral amygdaloid nucleus projection neurons in depressed patients by the AgNOR staining method.
     J Affect Disord, 126(3): 402-10. [Abstract] [Full-text]
125. Adverse life event reporting and worst illness episodes in unipolar and bipolar affective disorders: measuring environmental risk for genetic research.
     Psychol Med, 40(11): 1829-37. [Abstract] [Full-text]
126. Vascular diseases and old age mental disorders: an update of neuroimaging findings.
     Curr Opin Psychiatry, 23(6): 491-7. [Abstract] [Full-text]
127. Genetic and environmental influences on focal brain density in bipolar disorder.
     Brain, 133(10): 3080-92. [Abstract] [Full-text]
128. Vascular diseases and old age mental disorders: an update of neuroimaging findings.
     Curr Opin Psychiatry, 23(6): 491-7. [Abstract] [Full-text]
129. Adverse life event reporting and worst illness episodes in unipolar and bipolar affective disorders: measuring environmental risk for genetic research.
     Psychol Med, 40(11): 1829-37. [Abstract] [Full-text]

© 2004-2013 Bipolar Research Today. All Rights Reserved.